MCM
PDLI

Marathon Capital Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Marathon Capital Management’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-25,000
Closed -$79K – 101
2016
Q2 		$79K Hold
25,000
– – 0.04% 81
2016
Q1 		$83K Hold
25,000
– – 0.04% 80
2015
Q4 		$88K Hold
25,000
– – 0.05% 78
2015
Q3 		$126K Buy
+25,000
New +$143K 0.06% 78

Other funds holding PDLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $70.2B AUM 29.99% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Marathon Capital Management's PDLI Position: Q3 2016 in Review

Marathon Capital Management sold out of PDL BioPharma, Inc. (PDLI) in Q3 2016, closing a stake of 25,000 shares — an estimated $79K sold.

Marathon Capital Management first reported a position in PDLI in Q3 2015 and held it in 4 quarters. The position peaked at $126K in Q3 2015. 197 funds tracked by Wall St. Rank hold PDLI as of Q3 2016.

  • Marathon Capital Management reported no remaining PDL BioPharma, Inc. position as of Q3 2016 after selling out during the quarter.
  • Marathon Capital Management sold 25,000 PDL BioPharma, Inc. shares in Q3 2016, an estimated $79K.
  • Marathon Capital Management first reported a position in PDL BioPharma, Inc. in Q3 2015 and held it in 4 quarters.
  • Marathon Capital Management's PDL BioPharma, Inc. position peaked at $126K in Q3 2015.
  • 197 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2016.

Based on Marathon Capital Management's 13F filing for Q3 2016, filed 10 Nov 2016.